“It will also result in treatment resistance,” she said — strains of HIV that evolve to make medication ineffective ... over ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

In an interview with the AP, UNAIDS Executive Director Winnie Byanyima called on the Trump Administration not to cut off ...

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir ... the individuals studied are living ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy ... are living with HIV strains that have any known ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy ... are living with HIV strains that have any known ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called ... studied are living with HIV strains that have any known lenacapavir ...